Published in Lab Business Week, November 21st, 2004
Net revenue rose 31.2% to $198.4 million compared with last year's third quarter, reflecting continued growth in the company's core ophthalmic surgical and eye care businesses, and the benefits of the Pfizer acquisition. Excluding the effect of currency, revenue grew 25.3% for the third quarter, compared to the same period in 2003.
Pro forma net income for the third quarter of 2004 grew 64.7% to $11.3 million, or $0.29 per diluted share, compared to $6.9 million, or $0.23 per...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.